Yucel Selcuk, Kutlu Omer, Kukul Erdal, Baykara Mehmet
Department of Urology, Akdeniz University School of Medicine, Kampus, Antalya, Turkey.
Urology. 2004 Nov;64(5):1020-5; discussion 1025. doi: 10.1016/j.urology.2004.06.067.
To investigate the urodynamic profiles of adults with primary nocturnal enuresis (PNE) and the association of the urodynamic profile findings with the efficacy of desmopressin and/or tolterodine pharmacotherapy. At least 2% of adults are enuretic during the night. The diagnostic and treatment approach for PNE is empirically the same in children and adults.
A total of 20 nocturnal enuretic patients (12 women and 8 men) with a mean age of 27.1 years (range 20 to 42) were studied. They had wet their bed at least twice per week for the past 6 months. Urodynamic studies, including filling and voiding cystometry, pressure-flow study, and pelvic floor electromyography with superficial electrodes, were performed on all patients. Two of them had daytime symptoms, and two had prior failed desmopressin therapy. All patients began taking oral desmopressin 0.4 mg for 1 month. Their continence was assessed and tolterodine 4 mg was added for those in whom desmopressin alone failed. The patients responsive to desmopressin alone or desmopressin plus tolterodine were weaned from medication at 6 and 12 months to reassess continence. The mean follow-up period was 11.6 +/- 3.3 months (range 4 to 14).
Urodynamic studies of 20 PNE adult patients revealed detrusor instability in 10 (50%), hypocompliance in 8 (40%), nonneurogenic detrusor-sphincter dyssynergy in 1 (5%), and no abnormality in 10 (50%). Of the 20 patients, 19 (95%) had no voiding bladder problems. Of the 10 patients responsive to desmopressin alone, 6 (60%) had a normal urodynamic profile; the remaining 4 (40%) had detrusor instability and/or hypocompliance. Of the 5 patients who received desmopressin and tolterodine, 3 achieved continence. The overall continence rate was 86% (13 of 15), and 12 (92%) of the 15 patients required maintenance therapy. In 2 patients (13.3%), desmopressin and tolterodine therapy failed. The efficacy of desmopressin alone and of desmopressin plus tolterodine were not related to the urodynamic profile findings (P >0.05). The urodynamic profile was also not related to the relapse rate after any form of pharmacotherapy (P >0.05).
PNE persisting into adulthood may be associated with abnormal urodynamic findings. Patients may benefit from urodynamic studies, because if the findings are abnormal, they might have the best chance of successful treatment.
研究原发性夜间遗尿(PNE)成人患者的尿动力学特征,以及尿动力学检查结果与去氨加压素和/或托特罗定药物治疗疗效之间的关联。至少2%的成年人存在夜间遗尿情况。PNE的诊断和治疗方法在儿童和成人中经验性相同。
共研究了20例夜间遗尿患者(12名女性和8名男性),平均年龄27.1岁(范围20至42岁)。在过去6个月里,他们每周至少尿床两次。对所有患者进行了尿动力学检查,包括充盈性和排尿性膀胱测压、压力-流率研究以及使用表面电极的盆底肌电图检查。其中2例有白天症状,2例曾接受去氨加压素治疗但失败。所有患者开始口服0.4mg去氨加压素,持续1个月。评估他们的控尿情况,对于单用去氨加压素治疗失败的患者加用4mg托特罗定。对单用去氨加压素或去氨加压素加托特罗定有反应的患者,在6个月和12个月时逐渐减药以重新评估控尿情况。平均随访期为11.6±3.3个月(范围4至l4个月)。
20例PNE成年患者的尿动力学检查显示,10例(50%)存在逼尿肌不稳定,8例(40%)存在顺应性降低,1例(5%)存在非神经源性逼尿肌-括约肌协同失调,10例(50%)无异常。20例患者中,19例(95%)无排尿膀胱问题。在单用去氨加压素有效的10例患者中,6例(60%)尿动力学检查结果正常;其余4例(40%)存在逼尿肌不稳定和/或顺应性降低。在接受去氨加压素和托特罗定治疗的5例患者中,3例实现了控尿。总体控尿率为86%(15例中的13例),15例患者中有12例(92%)需要维持治疗。2例患者(13.3%)去氨加压素和托特罗定治疗失败。单用去氨加压素以及去氨加压素加托特罗定的疗效与尿动力学检查结果无关(P>0.05)。尿动力学检查结果也与任何形式药物治疗后的复发率无关(P>0.05)。
持续到成年期的PNE可能与异常的尿动力学检查结果有关。患者可能从尿动力学检查中获益;因为如果检查结果异常,他们可能有最佳的成功治疗机会。